Skip to main content

Eupraxia Pharmaceuticals Inc. (EPRX)

Sector
Healthcare
Industry
Biotechnology
Last price
$6.62
As of

Kresmion compiles this page from EPRX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.

EUPRAXIA PHARMACEUTICALS INC. (EPRX): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-11-10.

As of . Source: SEC EDGAR filings for EPRX. Method and limitations.

COMPANY DOSSIER

See the full EPRX dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for EPRX on one page. Preview it with sample data, then open it live with a free account.

Preview the EPRX dossier

Active events for EPRX

FREE, NO ACCOUNT

Every event on EPRX, as it fires

You are seeing 5 of 9 events recorded on EPRX since 2026-05-31.

The five above landed across 3 days. The other 4 were recorded on 2 other days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.

Recent SEC filings, EPRX

More data on EPRX

EPRX against its peers

EPRX's return on equity of -47.0% ranks in the 52nd percentile of 21 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.

MetricEPRXPeer medianPercentilen
Revenue FY0.0 USD7.3M USD1615
Operating marginn/a-387.5%n/a12
Net marginn/a-239.0%n/a12
Return on equity-47.0%-53.8%5221
1 year18.4%5.5%7021

Peers (22): CAPR, MYGN, ZVRA, VALN, SANA, ENTX, FTH, OBIO, SRZN, CBIO, RGNX, NGNE, GERN, CLYM, MNPR, CGEM, ABUS, WVE, OVID, DMAC, STTK, DSGN. Left out: IAM (no annual filing), SLBT (no annual filing), ETRA (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (EPRX: 40-F), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Cite this data

Kresmion counts the managers it follows that reported a non-option position in EPRX on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on EPRX in the last 180 days.

Upstream: SEC EDGAR filings for EPRX

Kresmion, "EUPRAXIA PHARMACEUTICALS INC. (EPRX) institutional holdings and SEC filings", data as of 2026-11-12, https://kresmion.com/research/EPRX. Upstream data: SEC EDGAR filings for EPRX.

Link to this data (HTML):

<a href="https://kresmion.com/research/EPRX">EUPRAXIA PHARMACEUTICALS INC. (EPRX) institutional holdings and SEC filings (Kresmion)</a>

Writing about this? Press contact and ready-to-quote figures

Follow EPRX on a live board

Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to EPRX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.

Preview the EPRX dossier
Share

The EPRX intelligence card: the smart money composite, cross family confluence and the top current signal, with a link back to this page.